• 股價
  • 漲跌
  • 漲幅
  • 成交量
The projected fair value for Moderna is US$151 based on 2 Stage Free Cash Flow to Equity
Current share price of US$79.01 suggests Moderna is potentially 48% undervalued
 Analyst price target for MRNA is US$140 which is 7.6% below our fair value estimate
Does the November share price for Moderna,
    From pandemic fatigue to vaccine fatigue — Americans are proving slow to follow the CDC’s advice to get a COVID-19 booster shot this fall.
    On Sept. 12, the CDC recommended that everyone six months and older should get an updated COVID-19 vaccine to protect against the potentially serious outcomes 
      Ron Baron (Trades, Portfolio), the esteemed founder of Baron Capital Management and a seasoned investor known for his long-term growth strategy, has made notable changes to his portfolio in the third quarter of 2023. With a keen eye for small to mid-size growth companies, Baron's investment philoso
        Warning! GuruFocus has detected 5 Warning Signs with MELI.
        Baillie Gifford (Trades, Portfolio), a century-old investment management partnership, is renowned for its commitment to long-term, bottom-up investing and fundamental analysis. The firm's recent 13F filing for Q3 2023 reveals strategic adj
          Personalis, Inc. (NASDAQ:PSNL) Q3 2023 Earnings Call Transcript November 7, 2023
          Personalis, Inc. beats earnings expectations. Reported EPS is $-0.48, expectations were $-0.54.
          Operator: Good afternoon and welcome to Personalis Third Quarter 2023 Earnings Conference Call. All participants will be